Lbmc Investment Advisors LLC cut its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 8.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,230 shares of the biopharmaceutical company’s stock after selling 723 shares during the quarter. Lbmc Investment Advisors LLC’s holdings in Pfizer were worth $422,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also bought and sold shares of the stock. Karp Capital Management Corp acquired a new position in Pfizer during the third quarter worth $27,000. Worth Asset Management LLC acquired a new position in Pfizer during the first quarter worth $29,000. Delos Wealth Advisors LLC raised its holdings in Pfizer by 100.0% during the third quarter. Delos Wealth Advisors LLC now owns 800 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 400 shares during the last quarter. Legend Financial Advisors Inc. acquired a new position in Pfizer during the third quarter worth $42,000. Finally, Align Wealth Management LLC acquired a new position in Pfizer during the fourth quarter worth $45,000. 67.62% of the stock is owned by institutional investors.
Pfizer Stock Performance
NYSE PFE opened at $40.10 on Friday. Pfizer Inc. has a 52-week low of $39.23 and a 52-week high of $56.32. The company has a 50-day simple moving average of $43.26 and a 200 day simple moving average of $46.03. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.00 and a current ratio of 1.22. The company has a market capitalization of $225.33 billion, a PE ratio of 7.32, a price-to-earnings-growth ratio of 1.33 and a beta of 0.64.
Wall Street Analysts Forecast Growth
PFE has been the topic of several research reports. BMO Capital Markets lowered their price objective on shares of Pfizer from $55.00 to $53.00 and set an “outperform” rating on the stock in a report on Wednesday, February 1st. Cantor Fitzgerald restated an “overweight” rating and set a $75.00 price objective on shares of Pfizer in a report on Wednesday, February 1st. Berenberg Bank set a $40.00 target price on shares of Pfizer in a report on Tuesday, February 7th. Jefferies Financial Group assumed coverage on shares of Pfizer in a report on Monday, March 6th. They issued a “hold” rating and a $43.00 target price for the company. Finally, The Goldman Sachs Group upgraded shares of Pfizer from a “neutral” rating to a “buy” rating and increased their target price for the company from $47.00 to $60.00 in a report on Tuesday, December 13th. Nine equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average price target of $50.38.
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.